How does the expiration of a pharmaceutical firms’ drug patent affect the firms’ R&D decisions? We attempt to answer this question by combining data from the FDA Orange Book dataset on drug patents with firm-level data from the Pharmaprojects database. We utilize a logistic probability model to determine how patent expiration affects the chances that a firm will undertake certain actions to mitigate the negative effects that patent expirations have on revenue streams. In doing so, we find that firms that are nearing patent expiration begin testing of new products and seek new licensing opportunities for existing products, rather than discontinue existing products.Bachelor of Art
Drawing on the reputation literature and signaling theory, this article builds on work that looks at...
This paper analyzes the effect of the changing nature of innovation on pharmaceutical firm market va...
We study the causal impact of patent invalidation on subsequent innovation and exit by patent holder...
How does the expiration of a pharmaceutical firms’ drug patent affect the firms’ R&D decisions? We a...
This paper investigates patterns of industrial dynamics and competition in the pharmaceutical indust...
This paper attempts to estimate the change in sales associated with pharmaceutical patent expiration...
This paper seeks to explain why some pharmaceutical companies are observed to withdraw their product...
Pharmaceutical firms typically enjoy market exclusivity for new drugs from concurrent protection of ...
OBJECTIVE: The aim of this study was to evaluate the impact of patent expiry on drug prices by means...
My research focuses on pharmaceutical patents and their effect on the availability of medicine. Beca...
Since Comanor and Scherer (1969), researchers have been using patents as a proxy for new product dev...
OBJECTIVE: The aim of this study was to evaluate the impact of patent expiry on drug prices by means...
PATENTS ARE a powerful tool for asserting intellectual property rights—they offer innovators profita...
Drawing on the reputation literature and signaling theory, this article builds on work that looks at...
URL des Cahiers : http://ces.univ-paris1.fr/cesdp/MSEFramCahier2006.htmCahiers de la Maison des Scie...
Drawing on the reputation literature and signaling theory, this article builds on work that looks at...
This paper analyzes the effect of the changing nature of innovation on pharmaceutical firm market va...
We study the causal impact of patent invalidation on subsequent innovation and exit by patent holder...
How does the expiration of a pharmaceutical firms’ drug patent affect the firms’ R&D decisions? We a...
This paper investigates patterns of industrial dynamics and competition in the pharmaceutical indust...
This paper attempts to estimate the change in sales associated with pharmaceutical patent expiration...
This paper seeks to explain why some pharmaceutical companies are observed to withdraw their product...
Pharmaceutical firms typically enjoy market exclusivity for new drugs from concurrent protection of ...
OBJECTIVE: The aim of this study was to evaluate the impact of patent expiry on drug prices by means...
My research focuses on pharmaceutical patents and their effect on the availability of medicine. Beca...
Since Comanor and Scherer (1969), researchers have been using patents as a proxy for new product dev...
OBJECTIVE: The aim of this study was to evaluate the impact of patent expiry on drug prices by means...
PATENTS ARE a powerful tool for asserting intellectual property rights—they offer innovators profita...
Drawing on the reputation literature and signaling theory, this article builds on work that looks at...
URL des Cahiers : http://ces.univ-paris1.fr/cesdp/MSEFramCahier2006.htmCahiers de la Maison des Scie...
Drawing on the reputation literature and signaling theory, this article builds on work that looks at...
This paper analyzes the effect of the changing nature of innovation on pharmaceutical firm market va...
We study the causal impact of patent invalidation on subsequent innovation and exit by patent holder...